Can you say "100%" in Indian pharma promotional material?

Conditionally restricted. '100%' is not banned outright in Indian pharmaceutical promotional material, but the claim it makes is restricted. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, information must be balanced, up-to-date, verifiable, must not mislead, and must be capable of substantiation (Clause 1.3). The Code also says it must not be stated categorically that a medicine has no side effects, toxic hazards, or risk of addiction (Clause 2.2).

In short

  • Status: conditionally restricted.
  • Governing instrument: Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 1.3, and Section 2 (Claims & Comparisons), Clauses 2.1 and 2.2. Also the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Section 4. Section 14(c) of that Act saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. The Act's other savings in Section 14, and exemptions under Section 15, also apply. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 also apply to Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). The conditions say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team.
  • UCPMP 2024 does not name this term.
  • First checked by two independent AI models against the live web. Citations re-checked on 6 October 2026. They were checked against the official texts of the Code, the Drugs and Magic Remedies Act and the CDSCO 2016 consolidated text of the Drugs Rules.

Which instrument governs this

Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 1.3, and Section 2 (Claims & Comparisons), Clauses 2.1 and 2.2. Also the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Section 4. Section 14(c) of that Act saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. The Act's other savings in Section 14, and exemptions under Section 15, also apply. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 also apply to Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). The conditions say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team.

UCPMP 2024 does not name this term. An absolute figure can be used only where the evidence shows exactly that result and the statement does not mislead. Clause 2.2 bars a categorical claim that a medicine has no side effects, toxic hazards, or risk of addiction. That holds whatever the evidence.

What verification returned

'100%' is not banned outright in Indian pharmaceutical promotional material, but the claim it makes is restricted. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, information must be balanced, up-to-date, verifiable, must not mislead, and must be capable of substantiation (Clause 1.3). The Code also says it must not be stated categorically that a medicine has no side effects, toxic hazards, or risk of addiction (Clause 2.2). The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 also applies to an advertisement for a drug. Section 4 of that Act bars false or misleading claims. The Act covers doctor-directed material too, but Section 14(c) saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. The Act's other savings in Section 14, and exemptions under Section 15, also apply. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 add a condition for Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). They say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team. Avoid absolutes and use qualified statements tied to the evidence.

How this was checked

Two independent AI models were asked the same question against the live web. They were Gemini 2.5 Pro with Google Search grounding, and OpenAI GPT-5 with web search. A third model then judged whether they agreed on the substance rather than the wording. Every source cited was fetched over HTTP to confirm it exists. A fetch confirms only that a source exists. It does not confirm that the source supports the statement. So on 6 October 2026 the citations on this page were re-checked. They were checked against the official texts of the Code, the Drugs and Magic Remedies Act and the CDSCO 2016 consolidated text of the Drugs Rules. They were corrected where they were wrong. Terms that did not reach agreement between the models are not published.

Sources checked

Frequently asked questions

Can you say "100%" in pharma promotion in India?

Conditionally restricted. '100%' is not banned outright in Indian pharmaceutical promotional material, but the claim it makes is restricted. Under the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, information must be balanced, up-to-date, verifiable, must not mislead, and must be capable of substantiation (Clause 1.3). The Code also says it must not be stated categorically that a medicine has no side effects, toxic hazards, or risk of addiction (Clause 2.2).

Which law and code govern the use of '100%'?

Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Clause 1.3, and Section 2 (Claims & Comparisons), Clauses 2.1 and 2.2. Also the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Section 4. Section 14(c) of that Act saves an advertisement 'sent confidentially in the manner prescribed under section 16 only to a registered medical practitioner'. The Act's other savings in Section 14, and exemptions under Section 15, also apply. The manufacturing licence conditions in the Drugs and Cosmetics Rules 1945 also apply to Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q)). The conditions say no advertisement of those drugs 'shall be made except with the previous sanction of the Central Government'. Their text sets no audience limit. How they apply to material addressed only to prescribers is a question for your regulatory team.

How reliable is this answer?

It was first checked on 10 September 2026 by two independent AI models, Gemini 2.5 Pro and GPT-5. Both worked against the live web, and their answers were adjudicated for agreement. Every cited source was fetched to confirm it exists. A fetch confirms only that a source exists. So on 6 October 2026 the citations were re-checked. They were checked against the official texts of the Code, the Drugs and Magic Remedies Act and the CDSCO 2016 consolidated text of the Drugs Rules. They were corrected where they were wrong. Terms that did not reach agreement are not published. The Code and the law change, so check against the source before relying on it.

Check it before MLR does

Collateral Advisor flags this term in the pages you upload, for your team to review in context.

Free trial, no card needed. MarketingSense is a pre-MLR advisory assistant. Your medical, legal and regulatory team still makes the final call.

What this page is based on

  • Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, Department of Pharmaceuticals
  • Drugs and Magic Remedies (Objectionable Advertisements) Act 1954
  • Drugs and Cosmetics Rules 1945, manufacturing licence conditions on advertising Schedule H, H1 and X drugs (for example Rules 74(p) and 78(q))
  • Consumer Protection Act 2019 and the CCPA Guidelines 2022, for advertising to the public

General guidance for pharmaceutical marketing teams in India, reviewed 10 September 2026. Regulation and its interpretation change, and this page may not reflect the current position. It is not legal, regulatory or medical advice and it does not replace your own medical, legal and regulatory review. Please verify against the source text before relying on anything here. ImpactPlus Ventures LLP accepts no liability for decisions taken on the basis of this page.